Immune evasion mechanisms and cutting-edge therapeutic strategies of PD-L1 pathway in oral squamous cell carcinoma: an umbrella review

Abstract

Background: Oral squamous cell carcinoma (OSCC), a significant health burden in developing nations, is linked to risk factors such as tobacco use, alcohol consumption, betel nut chewing, HPV infection, and genetic susceptibility. A hallmark of OSCC is impaired T cell function, driven in part by the PD-L1/PD-1 immune checkpoint pathway, which enables tumor immune evasion and progression. Despite growing interest in immunotherapy, a focused synthesis of PD-L1 expression and its clinical implications in OSCC remains limited. This review aims to consolidate existing evidence on PD-L1 in OSCC, evaluating its expression patterns, correlation with disease progression, and therapeutic relevance.

Methods: A systematic search was conducted across multiple databases to identify studies examining PD-L1 expression in OSCC and its relationship with clinicopathological parameters and immune response.

Results: The findings revealed a higher PD-L1 positivity in female patients, non-smokers, and non-drinkers. Positive PD-L1 expression rate correlated with poor differentiation, lymph node metastasis, and advanced TNM stage. Although it didn’t significantly impact overall survival, higher PD-L1 expression was observed in HPV-positive patients and correlated with increased CD8+ TIL levels.

Discussion: Understanding the role of PD-L1 in OSCC elucidates immune evasion mechanisms and offers insights into potential treatments, such as checkpoint inhibitors, for personalized therapies and innovative cancer treatments. This comprehensive synthesis provides valuable insights into the complex interplay between PD-L1 expression and OSCC progression, laying the groundwork for additional studies in this area.

Keywords

immune evasion / PD-L1 / oral squamous cell carcinoma / tumor infiltrating lymphocytes / immune checkpoints

References

[1] Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera SK, Kurrey NK, et al. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral Oncol. 2021; 121: 105451.

[2] Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018; 52: 228-40.

[3] Muthusamy M, Ramani P, Krishnan RP, K H, Sukumaran G, Ramasubramanian A. Oral Microflora and Its Potential Carcinogenic Effect on Oral Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cureus. 2023; 15: e33560.

[4] Surendran S, Krishnan RP, Ramani P, Ramalingam K, Jayaraman S. Role of Ceramide Synthase 1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Potential Linchpin for Tumorigenesis. Cureus. 2023; 15: e42308.

[5] Gintoni I, Vassiliou S, Chrousos GP, Yapijakis C. Review of Disease-Specific microRNAs by Strategically Bridging Genetics and Epigenetics in Oral Squamous Cell Carcinoma. Genes (Basel). 2023; 14: 1578.

[6] Y D, Ramani P, Yuwanati M, Ramalingam K, S G. MicroRNA Profiling in Circulating Exosomes in Oral Squamous Cell Carcinoma: A Systematic Review. Cureus. 2023; 15: e43235.

[7] Starzyńska A, Sejda A, Adamski Ł, Adamska P, Pęksa R, Sakowicz-Burkiewicz M, et al. The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part I: B7-H1 (PD-L1) and B7-DC (PD-L2). Postepy Dermatol Alergol. 2022; 39: 265-74.

[8] Beyaert S, Borys A, Baldin P, Dahou H, Magremanne M, Mahy P, et al. Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity. Oral Oncol. 2024; 154: 106869.

[9] Sasabe E, Tomomura A, Yamamoto T. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma. J Oral Pathol Med. 2024; 53: 310-20.

[10] Park R, Li J, Slebos RJC, Chaudhary R, Poole MI, Ferraris C, et al. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2024; 154: 106866.

[11] Kok VC. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Front Oncol. 2020; 10: 268.

[12] He J, Chen X, Xu M, Zhao J. Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis. Arch Oral Biol. 2020; 114: 104717.

[13] Yang W, Wong MCM, Thomson PJ, Li K, Su Y. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 2018; 86: 81-90.

[14] Tang H, Zhou X, Ye Y, Zhou Y, Wu C, Xu Y. The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis. Pathol Res Pract. 2020; 216: 152768.

[15] Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-García P. Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis. Oral Oncology. 2020; 106: 104722.

[16] Patel JJ, Levy DA, Nguyen SA, Knochelmann HM, Day TA. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck. 2020; 42: 774-86.

[17] Troiano G, Caponio VCA, Zhurakivska K, Arena C, Pannone G, Mascitti M, et al. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. Cell Prolif. 2019; 52: e12537.

[18] Cheng L, Chai C, Liu Y, Jiao J. First-line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study. Oncol Lett. 2024; 28: 352.

[19] Hayashi H, Nakagawa K. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Int J Clin Oncol. 2020; 25: 818-30.

[20] Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in Immune Responses. Front Immunol. 2019; 10: 1076.

[21] Polanczyk MJ, Hopke C, Vandenbark AA, Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res. 2006; 84: 370-8.

[22] Foy JP, Bertolus C, Michallet MC, Deneuve S, Incitti R, Bendriss-Vermare N, et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017; 28: 1934-41.

[23] Lu H, Kuang D, Zhou P, Zeng J, Xia Q, Wang J, et al. PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study. J Clin Pathol. 2025; 78: 88-95.

[24] Xu J, editor. Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy. Springer Singapore; 2020.

[25] Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, et al. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol. 2006; 42: 268-74.

[26] Dong Y, Wang Z, Mao F, Cai L, Dan H, Jiang L, et al. PD-1 blockade prevents the progression of oral carcinogenesis. Carcinogenesis. 2021; 42: 891-902.

[27] Ma S, Liu J, Jia R, Deng W, Jia J. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1^high with CD8/PD-1^high . Biomolecules. 2023; 13: 1014.

[28] Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019; 19: 105- 19.

[29] Kogashiwa Y, Yasuda M, Sakurai H, Nakahira M, Sano Y, Gonda K, et al. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Anticancer Res. 2017; 37: 1417-24.

[30] Kitichotkul K, Lertprasertsuke N, Kintarak S, Pongsiriwet S, Powcharoen W, Iamaroon A. Expression of PD-L1 is HPV/P16-independent in oral squamous cell carcinoma. Heliyon. 2022; 8: e10667.

[31] Kim HS, Lee JY, Lim SH, Park K, Sun JM, Ko YH, et al. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. Cancer Res Treat. 2016; 48: 527-36.

[32] Subramaniam N, Nambiar A, Dhar S, Thankappan K, Koyakutty M, Balasubramanian D, et al. Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma. Indian J Surg Oncol. 2021; 12: 408-14.

[33] Pakkanen P, Ilmarinen T, Halme E, Irjala H, Koivunen P, Pukkila M, et al. Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) - low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer. Virchows Arch. 2024; 485: 315-22.

[34] Soopanit T, Laokulrath N, Chayopasakul V, Pongsapich W. Prognostic value and clinicopathological status of PD-L1 expression and CD8+ TILs in oral squamous cell cancer patients with or without traditional risk factors. Head Neck. 2023; 45: 1017-25.

[35] Cho YA, Yoon HJ, Lee JI, Hong S, Hong SD. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol. 2011; 47: 1148-53.

[36] Bhardwaj M, Chiu MN, Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022; 41: 73-90.

[37] Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21: 1353-65.

[38] Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022; 13: 964442.

[39] Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol. 2020; 1248: 33-59.

[40] Yu Y, Ni Z, Xu Y, Zhang L, Liu Y, Zeng F, et al. Multi-Functional AIE Phototheranostic Agent Enhancing αPD-L1 Response for Oral Squamous Cell Carcinoma Immunotherapy. Small. 2024; 20: e2405470.

[41] Zou Y, Zhang H, Liu F, Chen Z, Tang H. Intratumoral microbiota in orchestrating cancer immunotherapy response. J Transl Int Med. 2025; 12: 540-2.